50,484 Shares in AtriCure, Inc. $ATRC Acquired by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC purchased a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 50,484 shares of the medical device company’s stock, valued at approximately $1,413,000. Susquehanna Fundamental Investments LLC owned approximately 0.10% of AtriCure as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ATRC. Bank of America Corp DE lifted its holdings in shares of AtriCure by 13.7% during the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after acquiring an additional 92,830 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in AtriCure in the second quarter valued at about $1,744,000. Rice Hall James & Associates LLC acquired a new position in shares of AtriCure during the second quarter worth about $3,755,000. F m Investments LLC purchased a new stake in shares of AtriCure in the fourth quarter worth about $2,872,000. Finally, Vanguard Group Inc. boosted its position in shares of AtriCure by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after buying an additional 62,861 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Trading Up 1.2%

ATRC opened at $48.92 on Wednesday. AtriCure, Inc. has a 12-month low of $25.36 and a 12-month high of $49.98. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The stock has a market capitalization of $2.49 billion, a PE ratio of 232.96 and a beta of 1.26. The firm’s fifty day moving average price is $38.70 and its 200 day moving average price is $32.41.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The company had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts expect that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Sven Wehrwein sold 25,000 shares of AtriCure stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total value of $946,000.00. Following the completion of the transaction, the director owned 40,518 shares in the company, valued at approximately $1,533,201.12. This trade represents a 38.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the sale, the insider owned 86,511 shares of the company’s stock, valued at $3,363,547.68. This trade represents a 6.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 53,616 shares of company stock valued at $2,149,994. 4.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ATRC shares. Canaccord Genuity Group boosted their price target on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st. Piper Sandler boosted their target price on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 27th. BTIG Research raised their price target on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 24th. Finally, Weiss Ratings upgraded shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.89.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.